Oncotarget 4(6):890-8, 2013
J Neurochem 71:25102517 Bogaert YE, Rosenthal RE, Fiskum G (1994) Postischemic inhibition of cerebral cortex pyruvate dehydrogenase
doi: 10.3389/fphar.2021.628651 Received 12 November 2020 Accepted 19 March 2021 Published 26 April 2021 Volume 12 - 2021 Edited by Akhilesh K Pandey, Texas Tech University Health Sciences Center, United States Reviewed by Shashank Kumar, Central University of Punjab, India Vasavi Gorantla, St.Georges University School of Medicine, Grenada Haripriya Vittal Rao, Wake Forest Baptist Medical Center, United States Tulika Mishra, Deen Dayal Upadhyay Gorakhpur University, India Updates Copyright 2021 Liu, Yang, Zhao, Tang, Duan, Zhou, Chen, Sun, Song, Hu and Shi
Five years after reaching the nadir of weight loss, 50.2% of the RYGB patients regained more than 15% of maximal weight loss and 86.5% regained more than 10% of maximal weight loss [3]
So far, several unimolecular dual and triple agonists are in clinical evaluation and as of today, the improved metabolic efficacy does not seem to be compromised by reduced safety [25].
Type: Tetrapeptide
